Nov 2, 2006
By:
Keith DiBlasi, Maik W. Jornitz, Uwe Gottschalk, PhD, Paul M. Priebe
Biopharmaceutical processes typically require a significant investment in equipment—often a substantial obstacle for start-up companies. The risk of drug development failure is often high, further limiting access to the required capital. Flexibility and lower capital outlays are required not only by start-up companies, but also by research organizations with multiple product lines and by companies requiring quick capacity increases. Disposable technologies offer the highest potential for these companies to meet their business requirements. With lower capital requirements and increased flexibility, disposables are an important part of these companies' risk management strategy.
|
|
Jun 1, 2005
By:
Uwe Gottschalk, PhD
In a mere 30 years of development, a total of 23 MAbs and MAb-related proteins have been approved for medical treatments.
|
Upstream and downstream processing must be aligned and integrated.
Mar 1, 2005
By:
Uwe Gottschalk, PhD
Revisiting simple, robust, and controllable
technology is the
only way
to overcome these challenges.
|
|
